Teva will acquire Allergan's generics unit for $40.5 billion. CNBC's Meg Tirrell takes a look at other potential M&A action in the space.» Read More
While the initial panic or hysteria may have dissipated, the threat of Ebola remains imminent, survivor Kent Brantly said.
Chart analyst John Kosar explains what could indirectly pull the rug out from under the U.S. stock market.
A woman diagnosed with HIV at birth is the longest to survive with no evidence of disease after stopping drug treatment.
Ireland-based Horizon Pharma raised its offer to buy Depomed to $33 per share from $29 per share, contingent on deal talks.
Novavax shares rose at Tuesday's market open after the bio-pharmaceutical firm said its Ebola vaccine showed promising early results.
Novartis saw sales fall in Q2, but it's optimistic about its pipeline, particularly heart disease drug Entresto, CEO Joe Jimenez says.
Discussing advancements in the effort to find a cure for Alzheimer's, with CNBC's Meg Tirrell and Fred Hassan, Warburg Pincus.
Medicines in development at Biogen, Eli Lilly and others may be the first to slow the cognitive declines associated with Alzheimer's disease. So how do they work? CNBC explains.
Biogen is looking to settle on one key thing: the perfect dose for its experimental Alzheimer's drug.
The Nasdaq composite, which lost its cachet as a benchmark after the dot-com bubble burst in 2000, is back on top. Can it keep going?
Mad Money host Jim Cramer explains why he likes Celgene's acquisition of Receptos, and the lesson for investors on smart speculation.
CNBC's Meg Tirrell reports investors like the Celgene-Receptos deal, and it is putting pressure on other biotech companies to merge.
CNBC's Meg Tirrell and Robert Hugin, Celgene chairman & CEO, discuss the drugmaker's $7.3 billion bid for Receptos in an effort to acquire a third autoimmune drug.
The 21st Century Cures Act passed House 344-77 today, reports CNBC's Meg Tirrell.
Earnings labels on over the counter pain drugs like Aleve, Advil, and Motrin will now contain stronger language about the risks of heart attack and stroke, reports CNBC's Meg Tirrell.
Researchers have raised a genetically engineered crop on land that contains certain nutrients found only in fish oil and algae.
Horizon Pharma said it offered to buy Depomed for about $3 billion, taking its bid hostile after the smaller drugmaker rejected the first proposal.
As sports grapples with the effects of injuries, one area of medicine is looking to make pain and recovery a thing of the past.
The FDA approved the use of Vertex Pharmaceuticals' Orkambi, a drug aimed to treat patients with cystic fibrosis.
The actor denounced new vaccination rules in California, but insists he is not anti-vaccine.
Get the best of CNBC in your inbox